Redeye returns with an update on Saniona. We are impressed by the company’s deal-making capabilities, having secured two landmark licensing agreements within the last twelve months. With a robust cash position and multiple programs approaching the clinic, we have incorporated several new projects into our valuation. Together with the Jazz agreement, this results in an increased valuation range.
